Sol-Gel Technologies EBITDA Margin 2016-2023 | SLGL
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Sol-Gel Technologies (SLGL) over the last 10 years. The current EBITDA margin for Sol-Gel Technologies as of December 31, 2023 is .
| Sol-Gel Technologies EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2023-12-31 |
$0.00B |
$-0.03B |
-1500.00% |
| 2023-09-30 |
$0.00B |
$-0.03B |
-1500.00% |
| 2023-06-30 |
$0.00B |
$-0.03B |
-1400.00% |
| 2023-03-31 |
$0.01B |
$-0.02B |
-420.00% |
| 2022-12-31 |
$0.00B |
$-0.02B |
-400.00% |
| 2022-09-30 |
$0.03B |
$0.00B |
16.00% |
| 2022-06-30 |
$0.03B |
$0.01B |
26.47% |
| 2022-03-31 |
$0.03B |
$0.00B |
3.23% |
| 2021-12-31 |
$0.03B |
$0.00B |
9.38% |
| 2021-09-30 |
$0.01B |
$-0.02B |
-138.46% |
| 2021-06-30 |
$0.01B |
$-0.03B |
-466.67% |
| 2021-03-31 |
$0.01B |
$-0.03B |
-466.67% |
| 2020-12-31 |
$0.01B |
$-0.03B |
-387.50% |
| 2020-09-30 |
$0.01B |
$-0.03B |
-310.00% |
| 2020-06-30 |
$0.01B |
$-0.03B |
-230.77% |
| 2020-03-31 |
$0.02B |
$-0.03B |
-135.00% |
| 2019-12-31 |
$0.02B |
$-0.03B |
-113.04% |
| 2019-09-30 |
$0.02B |
$-0.03B |
-136.84% |
| 2019-06-30 |
$0.01B |
$-0.02B |
-171.43% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.020B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
